8-K: Cocrystal Pharma Announces First Quarter 2024 Results and Provides Antiviral Program Updates

Cocrystal Pharma reported its Q1 2024 financial results and provided updates on its antiviral drug development programs, including progress on its influenza and coronavirus/norovirus treatments.

Summary

• Cocrystal Pharma released its financial results for the first quarter of 2024, showing a net loss of $4.0 million, or $0.39 per share, compared to a net loss of $5.2 million, or $0.64 per share, in the same period last year.
• Research and development expenses decreased to $3.0 million from $3.9 million year-over-year, primarily due to the progression of the CC-42344 influenza and CDI-988 dual norovirus-coronavirus programs into later-stage clinical studies.
• The company's cash balance was $21.8 million as of March 31, 2024, down from $26.4 million at the end of 2023.
• The company completed enrollment in the Phase 2a human challenge study for oral CC-42344 and expects topline results in the second half of 2024.
• Topline results from the single ascending dose (SAD) portion of the Phase 1 study for oral CDI-988 are expected in the second quarter of 2024, with the multiple ascending dose (MAD) portion planned for the second half of 2024.
• A Phase 1 study for inhaled CC-42344 is planned to begin in the second half of 2024.
• The company anticipates significant milestones this year and believes its cash will be sufficient to fund operations beyond the next twelve months.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials and reduced losses, but tempered by the ongoing cash burn and inherent risks in drug development.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Research and development expenses decreased, suggesting efficient resource allocation as programs advance.
• The company has completed enrollment in a Phase 2a study for CC-42344, a key milestone.
• The company has multiple clinical trials underway with results expected in the near term.
• The company anticipates its current cash reserves will fund operations for more than 12 months.

Negatives

• The company reported a net loss of $4.0 million for the quarter.
• The company's cash balance decreased from $26.4 million at the end of 2023 to $21.8 million as of March 31, 2024.
• Net cash used in operating activities increased to $4.5 million in Q1 2024 from $3.1 million in Q1 2023.

Risks

• The company faces risks related to high interest rates, financial market uncertainty, and potential recession.
• Geopolitical conflicts could impact the company, its partners, and the global economy.
• Manufacturing and research delays could arise from raw material and labor shortages.
• Supply chain disruptions and other business interruptions could affect the company's ability to proceed with studies.
• Clinical study results may not be favorable, and regulatory approvals are not guaranteed.
• Competitors may develop effective treatments or vaccines, impacting the company's market position.
• Viral mutations could lead to variants resistant to the company's product candidates.

Future Outlook

The company expects topline results from the Phase 2a human challenge study of oral CC-42344 and the SAD portion of the Phase 1 study of oral CDI-988 in the second half of 2024 and second quarter of 2024 respectively. They also plan to initiate a Phase 1 study of inhaled CC-42344 in the second half of 2024. The company believes its cash will be sufficient to fund operations beyond the next twelve months.

Management Comments

• Sam Lee, Ph.D., President and co-CEO of Cocrystal, stated that the coming months promise to be exceptionally eventful with major inflection points in their dual norovirus-coronavirus and influenza programs expected this year.
• James Martin, CFO and co-CEO of Cocrystal, mentioned that they continue advancing their development programs in high-value indications through a cost-efficient business model.

Industry Context

The announcement highlights Cocrystal Pharma's progress in developing antiviral treatments for influenza, coronaviruses, and noroviruses, which are significant global health threats. The company's focus on broad-spectrum antivirals aligns with the need for treatments that can address emerging variants and drug resistance. The estimated $16 billion COVID-19 therapeutics market by 2031 underscores the potential for the company's programs.

Comparison to Industry Standards

• Cocrystal's approach of using structure-based drug discovery differs from traditional methods, potentially leading to more effective and less toxic drugs, similar to companies like Vertex Pharmaceuticals that use structure-based design.
• The company's focus on broad-spectrum antivirals is similar to companies like Gilead Sciences, which has developed treatments for multiple viral diseases.
• The company's progress in clinical trials is comparable to other biotech companies in the early to mid-stage development phase, such as BioCryst Pharmaceuticals, which is also developing antiviral therapies.
• The company's reported cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway is a key metric to watch compared to peers.

Related Party Transactions

• Operating lease right-of-use assets and liabilities include amounts related to a related party.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and reduced losses.
• Employees may be motivated by the advancement of the company's programs.
• Customers (potential patients) may benefit from the development of new antiviral treatments.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• The company expects topline results from the SAD portion of the Phase 1 study for oral CDI-988 in the second quarter of 2024.
• The company expects topline results from the Phase 2a human challenge study of oral CC-42344 in the second half of 2024.
• The company plans to prepare an IND application to conduct a late-stage clinical study in the U.S. for CC-42344 in the second half of 2024.
• The company plans to initiate a Phase 1 study of inhaled CC-42344 in the second half of 2024.

Key Dates

Keywords

antiviral, clinical trials, influenza, coronavirus, norovirus, drug development, CC-42344, CDI-988, Phase 1, Phase 2a, biotechnology, R&D